INTERCURE LTD

INCRNASDAQ

US Equity

$0.96▲ $0.01 (+1.56%)

Live

1h—

24h▲ 1.6%

7d▼ 1.7%

14d▼ 2.3%

30d▼ 2.3%

1y▼ 44.2%

🏦Market Cap

$57M

Small Cap

📈Revenue Growth (YoY)

+45.1%

High Growth

📊Gross Margin

31.3%

Moderate

💵FCF Margin

7.0%

Moderate

⚖️P/S Ratio

0.3x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $0.96 – $0.97
52-Week Range: —
Volume: $1.65B
Avg Volume: $2.01B
Shares Outstanding: 59.2M
Next Earnings: Sep 23, 2026

Fundamentals Snapshot

Annual Revenue: $270M
Last Q Revenue: $70M
P/E Ratio: —
P/S Ratio: 0.3x
EPS (TTM): —
Dividend Yield: —

Why Investors Own INCR

✓High-growth profile — revenue up +20.8% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$270M▲ +16.2% YoY

Gross Margin (TTM)

26.8%▼ −0.3% YoY

Operating Income (TTM)

$62M▲ +16.2% YoY

Free Cash Flow (TTM)

$25M▲ +16.2% YoY

About INTERCURE LTD

InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.

🦦